Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.75 |
| ▸ | AR | P10275 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | IL1RN | P18510 | 1/20 | 0.66 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.66 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.66 |
| ▸ | KDM1A | O60341 | 1/20 | 0.63 |
| ▸ | ATIC | P31939 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 4/20 | 0.61 |
| ▸ | CA9 | Q16790 | 4/20 | 0.61 |
| ▸ | CA2 | P00918 | 3/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | GPR27 | Q9NS67 | 2/20 | 0.59 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
| ▸ | P4HB | P07237 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7572258 | 0.93 | CYP19A1 (0.75) | CYP19A1ARKMT2AMEN1ALDH1A1 | |
| SCHEMBL5040121 | 0.84 | KDM1A (0.61) | CYP19A1ARKDM1AATICCA2 | |
| SCHEMBL7281538 | 0.83 | KDM1A (0.68) | CYP19A1ARKDM1AATICCA12 | |
| SCHEMBL7572500 | 0.83 | CES1 (0.73) | CYP19A1ARALDH1A1KDM1ACA2 | |
| SCHEMBL27888183 | 0.83 | CA1 (0.65) | CYP19A1ARKMT2AMEN1ALDH1A1 | |
| SCHEMBL96241 | 0.83 | KDM1A (0.64) | CYP19A1ARKMT2AMEN1ALDH1A1 | |
| SCHEMBL5457170 | 0.83 | ALDH1A1 (0.63) | CYP19A1ARKMT2AMEN1ALDH1A1 | |
| SCHEMBL6554559 | 0.83 | CES1 (0.73) | CYP19A1ARALDH1A1KDM1ACA2 | |
| SCHEMBL6555449 | 0.83 | KDM1A (0.68) | CYP19A1ARKMT2AMEN1ALDH1A1 | |
| SCHEMBL20764443 | 0.82 | KDM1A (0.68) | CYP19A1ARKMT2AMEN1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2729454-B1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2015-09-16 | — | — | EP | disclosed |
| US-9056843-B2 | Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-06-16 | — | — | US | disclosed |
| US-20140142105-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | disclosed |
| EP-2729454-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013008162-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142105-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | HDAC4, HDAC5, HDAC6 | CYP19A1 1767/4885AR 913/4885KMT2A 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.